TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03642535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALA
Description: In all face treatment group, a 1-mm thick layer of 10% ALA was applied to the all face; In AK lesion treatment group, a 1-mm thick layer of 10% ALA was applied to the lesion and to 5 mm of surrounding healthy tissue. And Vehicle control cream was applied to the non-lesion area.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA
Description: In all face treatment group, a 1-mm thick layer of 10% ALA was applied to the all face; In AK lesion treatment group, a 1-mm thick layer of 10% ALA was applied to the lesion and to 5 mm of surrounding healthy tissue. And Vehicle control cream was applied to the non-lesion area.
Study: NCT01263067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifespan Integration Therapy
Description: LI treatment guides the client to imaginally visit past memories, and then leads her or him forward through time to the present using a concept referred to as the time line. Beginning with the individual's memories from the traumatic experience, the time line first follows memories from the days and weeks after the trauma, then season by season to the present, and is reviewed in ongoing sessions as increasing details of the traumatic event are uncovered.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifespan Integration- Control
Description: Participants selected for the control group will be treated 4 weeks following initial contact. Treatment is the same as for the Experimental Group.
Study: NCT03283046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Dose Escalation Phase Starting Dose: Nivolumab 1 mg/kg by vein over 60 minutes every 3 weeks for 4 doses, followed by Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle.~Dose Expansion Phase Starting Dose: Maximum tolerated dose (MTD) from Dose Escalation Phase.~Maintenance: Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose Escalation and Dose Expansion Dose: Lenalidomide 25 mg by mouth on Days 1- 14 in 21 day cycles and Days 1-21 in 28 day cycles.~Maintenance: Lenalidomide 10 mg by mouth on Days 1-21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dose Escalation and Dose Expansion Dose: Dexamethasone 40 mg by mouth on Days 1,8,15 in 21 day cycles and 1,8,15 and 22 in 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Dose Escalation and Dose Expansion Dose: Ipilimumab 1 mg/kg by vein over 90 minutes every 3 weeks for 4 doses.~Maintenance: If there is evidence of disease progression, Ipilimumab reintroduced at 3 mg/kg every 3 weeks for 4 doses. (Nivolumab dose in Combination determined by the phase 1 portion).
Study: NCT02964338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered as per the schedule specified in the respective arms.
Study: NCT02829658

Intervention type: BEHAVIORAL
Intervention: Psychologic test
Description: Assessment by a psychologist including the Structured Interview for Diagnostic and Statistical Manual (DSM)-IV Personality Disorders (SIDP-IV) was given straight to those who had a score above 28. This questionnaire allowed us to distinguish one group of subjects with BPD and a group with other PD (without BPD). Clinical evaluation included Axis I (MINI), Axis II (SIDP-IV), psychopathological features (YSQ-I, Defense Style Questionnaire (DSQ-40), demographic variables and therapeutic alliance (Haq-II).

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03094884

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pulsed Low Dose Radiation
Description: Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
Study: NCT02812641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPF-CCRT (run-in)
Description: Six patients will be enrolled in run-in phase. If \<= 1 patient developed dose-limiting toxicity, the trial will be continued to randomized phase. If \> 1 patients developed dose-limiting toxicities, the protocol will be discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPF-CCRT (randomized)
Description: Twenty-two patients will be planned to assign to the experimental arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-CCRT (randomized)
Description: Twenty-two patients will be planned to assign to the active control arm
Study: NCT01292707

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard national training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HW
Description: Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HWC
Description: The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.
Study: NCT03441685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semantic cues (perform action), syntactic cues (sentence frame), or combined semantic and syntactic cues
Description: Verb Learning Session Teaching phase. The examiner labels each target word and performs the action 6 times in each condition. She elicits the target word from the participant 2 times per word per condition and provides feedback on accuracy.~Testing phase. Receptive probes are administered after every 2 words are taught. Expressive probes are at the end of the condition. For receptive probes, the examiner asks the participant to identify novel verbs and for expressive probes, the examiner asks the child to label the novel action. Testing after 2 items is designed to decrease memory load. Participants have a brief break between conditions.~Data are collected on: a) child responses on standardized assessments, (b) responses to verb learning probes, (c) parent responses to intake form, and (d) relevant medical history from electronic medical record.~None of the above procedures present more than minimal risk to participants or research staff. Vanderbilt IRB approved all procedures.
Study: NCT01965002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRgHIFU
Description: The InSightec ExAblate 2000 magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325 mg PO for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 40 mg by subcutaneous (SC) administration, for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment
Study: NCT03397121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Study: NCT02380937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ablation for typical atrial flutter
Description: ablation for typical atrial flutter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vision Ablation Catheter
Study: NCT03540069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Group Cervical Cancer Screening Education Curriculum
Description: a multi-modal peer education curriculum directed at a multi-level audience and aimed at motivating women to seek cervical cancer screening services.
Study: NCT05637307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel node procedure
Description: Injection of radio-active tracer in the tumor before brachytherapy treatment, visualization of sentinel nodes by SPECT, and extirpation of sentinel nodes by surgery
Study: NCT03523195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete exercise program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive written information on healthy exercise and diet recommendations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Blood tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Blood tests

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring Device
Description: Wear Fitbit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance Testing
Description: Performance of physical tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Performance of physical tests
Study: NCT03791801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: the reversal of neuromuscular blockade with sugammadex compared to neostigmine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: the reversal of neuromuscular blockade with sugammadex compared to neostigmine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Both groups will receive rocuronium for paralysis during intubation
Study: NCT00720785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Parenteral formulation. It is supplied as a 3.5 mg single use vial containing a sterile lyophilized powder that requires reconstitution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: NK Cell Infusion
Study: NCT03791801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Both groups will receive rocuronium for paralysis during intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: The reversal of neuromuscular blockade with sugammadex compared to neostigmine/glycopyrrolate
Study: NCT02103023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod ointment
Description: 5% 250mg imiquimod ointment

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Imiquimod ointment
Description: 5% 250mg imiquimod ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous cream
Description: aqueous cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous cream
Description: aqueous cream

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal influenza vaccine
Description: intradermal trivalent influenza vaccine (Intanza15)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intradermal influenza vaccine
Description: intradermal trivalent influenza vaccine (Intanza15)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular influenza vaccine
Description: intramuscular trivalent influenza vaccine (Vaxigrip)
Study: NCT02683239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab
Description: Participants will receive sub-cutaneous (SC) injections of fasinumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab
Description: Participants will receive sub-cutaneous (SC) injections of fasinumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive sub-cutaneous (SC) injections of matching placebo
Study: NCT01296854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa therapy
Description: 3 weeks of spa therapy
Study: NCT01853683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative Management

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative Management
Study: NCT03352492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superior laser peripheral iridotomy
Description: Iridotomy placement between 11:00 and 1:00 o'clock

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporal laser peripheral iridotomy
Description: Iridotomy placement at 3:00 or 9:00 o'clock
Study: NCT04152083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Injection for IV administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection for IV administration
Study: NCT02064699

Intervention type: BIOLOGICAL
Intervention: CMV Infection
Description: Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for.~Using the QuantiFERON-CMV test for predicting the risk of CMV infection in the transplanted immune against CMV.
Study: NCT03711305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: SHR-1316 intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6) and maintenance phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6) and maintenance phase.
Study: NCT02858271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-9778 subcutaneous injection
Study: NCT05035875

Intervention type: DEVICE
Intervention: ultrasonography
Description: ultrasound assessment of diaphragm function

Intervention type: DEVICE
Intervention: ultrasonography
Description: ultrasound assessment of diaphragm function
Study: NCT00809536

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: 225 mg q12, oral PD 0332334 immediate release formulation on Days 1 through 5; Single, oral, 500 mg dose of metformin immediate release

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Single, oral, 500 mg of metformin immediate release

Intervention type: DRUG
Group type: OTHER
Intervention: PD 0332334
Description: 500 mg q12, oral metformin immediate release administered on Days 1 through Day 6 Single, oral, 300 mg dose of PD 0332334 immediate release formulation administered on Day 3

Intervention type: DRUG
Group type: OTHER
Intervention: PD 0332334
Description: Single, oral, 300 mg dose of PD 0332334 immediate release formulation
Study: NCT03943355

Intervention type: OTHER
Intervention: Patient before cohort (2005-2010)
Description: The NOM protocol with AE was recognized and accepted after our previous study reported in 2004.

Intervention type: OTHER
Intervention: Patient after cohort (2011-2016)
Description: The protocol of NOM became more aggressively and strictly adhered to since 2011.
Study: NCT04391179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole 100 Milligram(mg)
Description: Drug will be given for 14 days while in the hospital.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo will be given for 14 days while in the hospital.
Study: NCT04553081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual versus triple therapy in treatment of HIV-1 infection.
Description: cfr arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual versus triple therapy in treatment of HIV-1 infection.
Description: cfr arm description
Study: NCT00716807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine plus naloxone
Description: Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nalbuphine plus placebo
Description: Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine plus naloxone
Description: Patient group: burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nalbuphine plus placebo
Description: Patient group: Burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
Study: NCT01831427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection
Study: NCT04137107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given standard of care oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given standard of care oxaliplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Given standard of care oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given standard of care oxaliplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Given standard of care oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03936400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-based intervention and and evaluation of effectiveness in increasing adjustment of sexuality and intimacy
Description: Three face-to-face therapeutic conversations and an optional web-based evidence based information (about sexual consequences of cancer treatment)